Back to Search Start Over

Revisiting the interaction between complement lectin pathway protease MASP-2 and SARS-CoV-2 nucleoprotein.

Authors :
Bally I
Drumont G
Rossi V
Guseva S
Botova M
Reiser JB
Thépaut M
Dergan Dylon S
Dumestre-Pérard C
Gaboriaud C
Fieschi F
Blackledge M
Poignard P
Thielens NM
Source :
Frontiers in immunology [Front Immunol] 2024 Jun 07; Vol. 15, pp. 1419165. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024).
Publication Year :
2024

Abstract

Complement activation is considered to contribute to the pathogenesis of severe SARS-CoV-2 infection, mainly by generating potent immune effector mechanisms including a strong inflammatory response. Involvement of the lectin complement pathway, a major actor of the innate immune anti-viral defense, has been reported previously. It is initiated by recognition of the viral surface Spike glycoprotein by mannose-binding lectin (MBL), which induces activation of the MBL-associated protease MASP-2 and triggers the proteolytic complement cascade. A role for the viral nucleoprotein (N) has also been reported, through binding to MASP-2, leading to protease overactivation and potentiation of the lectin pathway. In the present study, we reinvestigated the interactions of the SARS-CoV-2 N protein, produced either in bacteria or secreted by mammalian cells, with full-length MASP-2 or its catalytic domain, in either active or proenzyme form. We could not confirm the interaction of the N protein with the catalytic domain of MASP-2 but observed N protein binding to proenzyme MASP-2. We did not find a role of the N protein in MBL-mediated activation of the lectin pathway. Finally, we showed that incubation of the N protein with MASP-2 results in proteolysis of the viral protein, an observation that requires further investigation to understand a potential functional significance in infected patients.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.<br /> (Copyright © 2024 Bally, Drumont, Rossi, Guseva, Botova, Reiser, Thépaut, Dergan Dylon, Dumestre-Pérard, Gaboriaud, Fieschi, Blackledge, Poignard and Thielens.)

Details

Language :
English
ISSN :
1664-3224
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
38911852
Full Text :
https://doi.org/10.3389/fimmu.2024.1419165